Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus radiotherapy vs S-1 plus radiotherapy in elderly advanced esophageal squamous cell carcinoma
ChiCTR2100051904Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing anlotinib + radiotherapy with Control: S-1 (Sigio) + radiotherapy (2 arms). Primary endpoint: 1-year locoregional recurrence-free survival. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
anlotinibtegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100051904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051904.